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Due to coexistence of stromal and epithelial tumor cells, their dynamic interactions have been widely recognized as significant
cellular components to the tumor tissue integrity. Initiation and outcome of epithelial to mesenchymal transition (EMT) in
tumor cells are dependent on their interaction with adjacent or recruited mesenchymal stromal cells (MSCs). A plethora of
mechanisms are involved in MSCs-controlled employment of the developmental processes of EMT that contribute to loss of
epithelial cell phenotype and acquisition of stemness, invasiveness and chemoresistance of tumor cells. Interplay of MSCs with
tumor cells, including interchange of soluble biomolecules, plasma membrane structures, cytoplasmic content, and organelles,
is established through cell–cell contact and/or by means of paracrine signaling. The main focus of this review is to summarize
knowledge about involvement of MSCs in cancer cell EMT. Understanding the underlying cellular and molecular mechanism
involved in the interplay between MSCs and cancer EMT is essential for development of effective therapy approaches, which
in combination with current treatments may improve the control of tumor progression. Developmental Dynamics 247:359–367,
2018. VC 2017 Wiley Periodicals, Inc.
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Introduction
It is now accepted that tumors are heterogeneous entities com-
prised by cells of multiple lineages, the extracellular matrix
(ECM) and soluble molecules (Tlsty and Coussens, 2006). Further-
more, the tumor stroma or tumor microenvironment (TME),
which includes several types of noncancerous cells and connec-
tive tissue, structurally and functionally supports cancer develop-
ment (Eng et al., 2009). The tumor stroma is a complex mixture
of cells, including local fibroblasts, smooth muscle cells, adipo-
cytes, endothelium, pericytes, and various types of inflammatory
cells, as well as extracellular matrix components (including struc-
tural proteins collagen, fibronectin, and proteoglycans, among
others), whereas the interstitial fluid contains a variety of soluble
inflammatory mediators and growth factors. TME has been rec-
ognized as a permissive or supporting feature for the tumor pro-
gression in epithelial cancers. Today, it is accepted that TME is
not only an ‘innocent bystander’ actor, because it plays an
important and active role in every step of epithelial cells tumori-
genesis (Quail and Joyce, 2013). From some viewpoints, tumor
development is dependent on physiologic response of tissue to
aberrant TME (Barcellos-Hoff and Medina, 2005).
Stromal and epithelial cells may interact through direct cell–
cell contac or by means of paracrine signaling as both cell popu-
lations produce a variety of matrix proteins, growth factors, pro-
teases and their inhibitors, and cytokines (Hemmings, 2013).
Importantly, stromal cells actively participate in the process of
epithelial to mesenchymal transition (EMT). Due to their tumor-
homing capacity and evident paracrine activity mesenchymal
stromal cells (MSCs), also referred to as multipotent stromal cells
or mesenchymal stem cells (Spees et al., 2016) are found also to
be important players in tumor progression (Shi et al., 2016).
In this review, we use MSCs abbreviation for the mesenchymal
stromal cells, as is proposed by the International Society for Cel-
lular Therapy (Dominici et al., 2006). MSCs are recognized as het-
erogenic population tissue-specific stromal cells involved in
homeostasis and repair of normal and injured tissues, with low
frequency of “true” mesenchymal stem cells within (Lindner
et al., 2010; Nombela-Arrieta et al., 2011; Robey, 2017). MSCs
could be isolated from various adult connective tissues, while
they are identified according to the Dominici et al. criteria (2006),
considering surface marker expression (CD73, CD105, and CD90),
in vitro tri-lineage differentiation (osteoblasts, adipocytes, and
chondrocytes) and plastic adherence. Importantly, the in vivo
functionality of MSCs is poorly understood and revealed, while
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most data obtained from in vitro studies are without rigorous assays
for testing self-renewal and multipotency of their progeny.
In cancer, MSCs may have incidence to poorer outcomes, and
they home within and support tumor progression, cell motility,
and invasiveness that enhance cancer cell metastatic potential.
Furthermore, they contribute to the colonization at secondary
organs (Ridge et al., 2017; Melzer et al., 2017). In this review, we
attempt to mainly describe the mechanism and capacity of MSCs
to modulate cancer EMT program as well as their involvement in
the reverse program mesenchymal to epithelial transition (MET),
whose balance contributes to consolidate tumor malignancy and
metastasis.
Mesenchymal Stromal Cells Within Tumor
Microenvironment
Mesenchymal gene signature in tumors has been implicated in
cancer transcriptome, recurrence, metastasis, and poor prognosis
of patients (Ridge et al., 2017). The source of these mesenchymal
signals has been mostly attributed to the EMT-like phenotype of
epithelial tumor cells. In addition MSCs can be involved in devel-
opment of mesenchymal tumors also, acquiring somatic muta-
tions during the proliferative phase of wound healing process
(Carothers et al., 2012; Mohseny and Hogendoorn, 2011). The
presence of MSCs within the tumor has been corroborated by sev-
eral studies that efficiently isolated them from tumor samples. It
is described that noncancerous mesenchymal stromal cells can be
isolated from human osteosarcoma specimens in high frequency
(Brune et al., 2011). Also, MSCs were isolated from sarcoma tissues
where they reside in perivascular regions (Morozov et al., 2010). Fur-
thermore, infiltration of mouse Lin-Sca-1þCD9þCD44þCD166þ/
MSCs was described in GL261 murine glioma model, signed as
brain tumor MSCs, which correlated to the brain tumor progres-
sion (Behnan et al., 2014). Similarly, MSCs are presented in breast
cancer microenvironment, contributing to proliferation, migra-
tion, and tumor progression of MCF-7 tumor cell line in vitro
(Zhang et al., 2013; Gonzalez et al., 2017). Similarly, efficient iso-
lation of stromal cells with characteristics of MSCs from human
gastric epithelial cancer, ovarian, and lung carcinoma was
reported (Berger et al., 2016). More precisely, immunophenotyp-
ing analysis of human ovarian tumor ascites demonstrated that
cells with the surface protein expression pattern of MSCs
(CD44þCD73þCD90þ) were relatively abundant (approximately
6% of cells; ranging from 1% to 11%), while in prostate cancer
MSCs represented approximately 0.01 to 1.1 % of the total cells
of tumor sample mass (McLean et al., 2011; Brennen et al., 2013).
Although MSCs are widely distributed in TME, where they per
se communicate with other cells and participate in the tumor
development, bone marrow also contributes to the number of
tumor-associated MSCs because these cells can also be mobilized
and recruited into TME in response to the tumor inflammatory
milieu (Quante et al., 2011). Moreover, MSCs also have capacity
to transdifferentiate into cancer-associated fibroblasts (CAFs) by
achieving “activated phenotype” and tumor-supporting feature
(Shangguan et al., 2012; Jung et al., 2013). Due to heterogeneity
within cells in the CAF population and their unresolved origin,
many intermediate populations occurring during their context-
specific lineage commitment, and cellular plasticity, there is still
no consensus regarding defined phenotype and function of CAFs
in TME (Kalluri, 2016; Trivanović et al., 2016a).
Nevertheless, the transition of MSCs toward CAFs has been
described as crucial event for the development of EMT program
of cancer cells (Jung et al., 2013). Moreover, MSCs or CAFs play
an important role not only in primary tumor TME but also in
metastatic niche. Specifically, metastatic breast mesenchymal
stromal-type cancer cells can adjust feature of highly secretory
lung mesenchymal fibroblasts, and alpha-smooth muscle actin
and fibroblast activation protein to achieve CAF-properties. Fur-
thermore, such activated stromal cells sustain MET of breast
mesenchymal-type cancer cells, thus favoring survival of cancer
cell in distant niches and consolidate metastasis.
During MET, breast cancer cells regained epithelial phenotype
through an inhibition of transforming growth factor b (TGF-b)
signaling and the stimulation bone morphogenetic protein sig-
naling, allowing cancer cell metastatic outgrowth in lungs (del
Pozo Martin et al., 2015). Importantly, MSCs are constituents of
bone marrow stroma, which is often targeting place for meta-
static breast, prostate, or lung cancer cells. MSCs participate in
process of bone remodeling, involving osteoclast-mediated bone
resorption resulting in the release of a multitude of growth fac-
tors, cytokines, and cell adhesion molecules from the bone
matrix, and then create the bone as an attractive site for meta-
static tumor cells.
Once in the bone microenvironment, tumor-derived growth
factors prime the bone for subsequent colonization of tumor cells
(Ottewell et al., 2015). Collectively, these data suggest that MSCs,
either resident or recruited to the tissue, can achieve “activated
secretory phenotype” by displaying CAF-associated properties
and by their contribution in critical steps of cancer EMT (Fig. 1).
Moreover, MSCs may play a role in the balance of EMT and MET
in cancer cells, which is closely linked to stemness in develop-
ment and cancer (Lamouille et al., 2014).
Cancer Cell EMT
EMT is a reversible embryonic genetic program, during which
motile cells can be generated from polarized sessile epithelial
cells. In addition, EMT is naturally occurring transdifferentiation
program. The reprogramming of the terminally differentiated
adult cells into induced pluripotent stem cells makes almost any
type of dedifferentiation or transdifferentiation a possible event
(Ye and Weinberg, 2015). EMT is a complex multistep process in
which phenotype switches are mediated by a network of tran-
scription factors (TFs). Systematic characterization of all dynamic
TFs controlling EMT state transitions, especially for the interme-
diate partial-EMT state, represents a highly relevant yet mostly
unrevealed issue (Chang et al., 2016). Currently, EMT is divided
into three subtypes, which are associated with distinct biological
functions: (1) embryogenesis and organ development, (2) tissue
regeneration, organ fibrosis and wound healing process, (3) can-
cer progression and metastasis. EMT (3) plays a central role dur-
ing tumor metastasis and frequently imparts a stem cell-like
phenotype and therapeutic resistance to tumor cells (Kalluri and
Weinberg, 2009; Ottewell et al., 2015).
Cancers of epithelial origin (carcinomas) have been mostly
described at the invasive point of the primary tumor mass, simulta-
neously indicating an important role of microenvironmental cues
generated by the surrounding stroma in the transdifferentiation
process. It is accepted that most human cancers arise either from
epithelial cells or their progenitors (Macara and McCaffrey, 2013).
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associated with the loss of cell–cell adhesions in favor of cell–ECM
interactions and cell motility (Thiery et al., 2009). Adherent junc-
tions are organized by N- and P-cadherin which mediate weak and
transient connections and are associated with motility cells. P-
cadherin is expressed in progenitor cells in myoepithelium of the
differentiated breast tissue, but is up-regulated in breast cancers.
N-cadherin is associated with mesenchymal state, and the
switch from E- to N-cadherin is a major hallmark of EMT
(Lamouille et al., 2014). Moreover, the repression of the apical
tight junctions’ protein expressions, such as occluding, claudins,
desmoplakin and plakophilin, during EMT contribute to the
establishment of the loss of cell–cell interaction and epithelial
barrier function by preventing de novo formation of epithelial
cell–cell junctions (Huang et al., 2012; Lamouille et al., 2014; Yu
and Elble, 2016).
The EMT process is initiated by the activation of EMT-
associated TFs, including Snail, zinc-finger E-box-binding (ZEB),
and Twist1, which drive the loose epithelial phenotype of cancer
cells by reducing the expression of the adherens junction pro-
teins, such as E-cadherin, and stimulate the expression of mesen-
chymal markers (Donnenberg and Donnenberg, 2015). As the loss
of E-cadherin expression is considered as a crucial event in EMT,
the EMT-associated TFs can be classified on the basis of their
ability to repress E-cadherin directly or indirectly. For instance,
direct repressors include: zinc finger proteins of the SNAIL super-
family, such as SNAI1 (also known as Snail), SNAI2 (SLUG), and
SNAI3 (SMUC); ZEB1 (TCF8), and ZEB2 (SIP1); the basic helix-
loop-helix (bHLH) factor E47; and the Kr€uppel-like factor KLF8.
Meanwhile, TFs, such as the bHLH proteins (TWIST1 and
TWIST2), the homeobox proteins goosecoid (GSC) and SIX1, the
bHLH factor E2.2, and the forkhead-box protein FOXC2 indirectly
repress E-cadherin transcription (Puisieux et al., 2014; Sato et al.,
2016). The functions of TFs are regulated at the transcriptional,
translational, and posttranslational levels, which are particularly
controlled by TGF-b signaling (Lamouille et al., 2014), as it is
known that although TGF-b acts a tumor suppressor at early step
of tumorigenesis, it stimulates EMT and malignancy of cancer
cells in later stages of malignant progression (Moustakas and
Heldin, 2016; Costanza et al., 2017).
Tumor cells undergoing EMT are invasive; resistant to senes-
cence, anoikis, and chemotherapeutics; and finally display stem-
ness characteristics (Heerboth et al., 2015). EMT-associated TFs
can reduce oncosuppressive mechanisms in cells that maintain
epithelial traits, thereby overcoming the mutation bottleneck
toward invasiveness. It is important to note that EMT is a potent
source of phenotypic, metabolic and functional tumor cell plas-
ticity (Puisieux et al., 2014). Furthermore, it is accepted that EMT
can generate tumor cells having stem cell characteristics which
phenotypically correspond to cancer stem cells (CSCs).
However, increasing evidence suggests that CSCs are tumor
cells in intermediate state of EMT which express reduced levels of
E-cadherin and increased mesenchymal markers associated with
stemness and invasiveness and finally metastasis (Prieto-Garcıa
et al., 2017; Shibue and Weinberg, 2017). In addition to CSCs, cir-
culating tumor cells (CTCs) have also been shown to exhibit prop-
erties of EMT, while EMT has been postulated to be involved in
CTC formation. For instance, the phenotypic analysis of CTCs
from patients with metastatic breast cancer revealed that a signif-
icant number of CTCs exhibited a partial or a full EMT phenotype
(Thiery and Lim, 2013; Yu et al., 2013). In addition, it has been
observed that breast CTCs occurred as single cells or multicellular
clusters, possessing mesenchymal properties and EMT regulators,
activated TGF-b signaling along with expression of FOXP C1
transcriptional factor at gene level (Yu et al., 2013).
Intriguingly, EMT has been mostly studied in carcinoma, but
there is growing evidence suggesting that cancers of organs
derived from mesoderm (e.g., hematopoietic malignancies and
sarcomas) (Sanchez-Tillo et al., 2014; Chou and Yang, 2015) or
ectoderm (e.g., glioblastomas and melanomas) (Iwadate, 2016)
also undergo EMT program to acquire an undifferentiated/mesen-
chymal profile (Sayan, 2014).
Modulation of Cancer Cell EMT Program by
MSCs
MSCs promote cancer cell EMT program: MSCs communicate
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production of proteins/peptides; transfer of mitochondria through
tunneling nanotubes and transfer of exosomes or microvesicles
containing RNA and other molecules (Fig. 1). Actually, MSCs
secrete various factors (cytokines, chemokines, and growth fac-
tors) and metabolites, such as prostaglandin E2, kynurenine,
galectin-1, or release exosomes or microvesicles, containing pro-
teins, mRNAs, and microRNAs altering features of tumor cells
(Hass and Otte, 2012).
In addition to paracrine communication, MSCs can establish
direct connection with tumor cells building gap junctions for
intercellular communication, which in turns allow modification
of signaling pathways (such as Notch signaling) in tumor cells
(Plaks et al., 2015). Thus, aforementioned MSCs mechanisms
provide to them the opportunity to influence EMT program at
different cellular and molecular levels (Figs. (1 and 2)). MSCs
stimulate cancer-associated EMT and induce stem-like properties,
which provides cancer cells with the increased motility and
invasive capabilities, together with cell survival in the circulation
and in distant metastatic niches (Lazennec and Lam, 2016)
(Fig. 2).
Notably, stromal-derived TGF-b is implicated in EMT of adja-
cent epithelial cells, while level, activation and bioavailability of
TGF-b is high through the production of proteases, integrins and
reactive oxygen species by the noncancerous cell compartments
expression, including infiltrating immune cells and MSCs, which
are dysregulated within tumor stroma. In contrast, stromal cells
can be source of molecules, such are proteoglycans, fibrillins,
fibulins and fibronectin, which can impair TGF-b availability
and activity in cancer cells (Costanza et al., 2017).
Importantly, MSCs can be “educated” or primed in vitro by
inflammatory factors to increase its capacity to induce cancer
EMT. Conditioned medium of MSCs prestimulated with both of
tumor necrosis factor-alpha (TNF-a) and interferon-gamma (IFN-
g) provokes EMT in breast cancer MCF-7 cells and pancreatic
adenocarcinoma (PANC-1 and BxPC-3) cell lines. The priming of
MSCs with these inflammatory factors induced elevated levels of
TGF-b production by MSCs which in turn stimulated EMT in
these both types of cancer cells (Trivanović et al., 2016b; Zhou
et al., 2016). These studies suggest that an inflammatory tumor
microenvironment produces an “activation state” of MSCs with
the consequent increased expression of TGF-b that enhances cell
malignancy and induces the EMT program both in vitro and in
vivo.
In addition, it has been demonstrated that the elevated TGF-b
expression by preconditioned MSCs with IFN-g and TNF-a, indu-
ces both in vitro and in vivo autophagy and chemoresistance of
hepatocellular carcinoma cell lines MMC-7721 and Hep-G2 (Han
et al., 2014).
Moreover, it has been suggested that na€ıve MSCs are recruited
and also “educated” or reprogrammed by gastric tumor cells.
Results also point to GSC-MSCs conditioned media and hepato-
cyte growth factor (HGF)-mediated phosphorylation of c-MET
downstream signaling which confer in vivo growth properties to





















Fig. 2. Converse effects of MSCS son tumor cell EMT. TGF-b, IL-6, PDGF, HGF, NO, and miR-20 activate EMT-associated TF in tumor cells,
leading to up-regulated expression of mesenchymal and stem cell markers (left, blue arrow). Inhibition of EMT-associated events by MSCs-
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Similarly, effects of Senescence-associated secretory pheno-
type of MSCs have been suggested to have inducible roles in EMT
of tumor cells (Laberge et al., 2012). Senescent stromal cells
exposed to hypoxia, have been suggested to promote prostate
cancer aggressiveness by inducing EMT. Hypoxia-induced miR-
210 in young fibroblasts increases their senescence-associated
features and converts them into cancer associated fibroblast-like
cells, which promotes cancer cells EMT of prostate cancer cell
line PC-3 in co-culture system, as demonstrated by the up-
regulation of ZEB1, ZEB2, and vimentin and the down-regulation
of E-cadherin EMT markers (Taddei et al., 2014).
Also, it has been observed that rat bone marrow MSCs (BM-
MSCs) increased the migration and stimulated the expression of
CXC chemokine receptor 4 (CXCR4) and F-actin remodeling in
rat hepatoma cells, CBRH-7919 (Li et al., 2015a). In addition,
cytoskeletal changes were observed in nasopharyngeal carcinoma
(NPC) cells after co-cultivation with BM-MSCs. Nitric oxide (NO)
produced by BM-MSCs could translocate caldesmon to podosome
in Ca2þ/calmodulin manner thus promoting metastatic ability of
carcinoma cells through invadopodia formation, with which the
NPC cells degrade the extracellular matrix (Zhang et al., 2014).
Additionally, autophagy has been shown also to be involved in
regulation of cancer cell EMT. Moreover, the role of autophagy
induced by various metabolic stressors (hypoxia, inflammation,
starvation) in the tumor microenvironment is bidirectional. Actu-
ally, autophagy can suppress tumorigenesis before tumor devel-
opment, while enhancing survival (resistance to anoikis) and
metastasis of tumor cells after tumorigenesis events (Yang et al.,
2015; Mowers et al., 2017; Gugnoni et al., 2016).
Intriguingly, through paracrine activity MSCs can induce
EMT-associated stemness in breast tumor cells. It has been dem-
onstrated that conditioned media from adipose tissue stem cells
(ASCs) promotes the frequencies of CD44high/CD24low CSCs
within 4T1 breast cancer cell population. In addition, ASCs
induced expression of mesenchymal markers, fibronectin, alpha
SMA and vimentin in breast cancer cells. This study revealed that
platelet-derived growth factor-D (PDGF-D) produced by ASCs is
involved in enhanced EMT of breast tumor cells in vivo (Devara-
jan et al., 2012). Also, BM-MSCs promotes de novo production of
lysyl oxidase (LOX) by breast cancer cells, which is sufficient to
enhance the metastasis to the lungs and bones.
Moreover, LOX is component of the CD44/Twist signaling axis.
Extracellular hyaluronan induces nuclear translocation of CD44
in the breast cancer cells, triggering LOX transcription. Enzymati-
cally active LOX stimulates Twist transcription, which mediates
the MSCs-induced EMT of breast cancer cells. However, as LOX is
critical for EMT but not for generation of CSCs, this study indi-
cated distinct signaling pathways underlying the EMT and CSC
generation within breast cancer cells (El Haibi et al., 2012).
In addition, it has been demonstrated that umbilical cord MSCs
(UCMSCs)-derived conditioned media decreased E-cadherin
expression, increased the expression of N-cadherin, and
enhanced the expression of ZEB1, through activation of the ERK
pathway in breast cancer cell lines MCF-7 and MDA-MB-231 (Li
et al., 2015b). Furthermore, three-dimensional cultured hepato-
cellular carcinoma (HCC) cells were subjected to EMT by UC-
MSCs co-culture. Also, HCC cells increased invasive capacities
concomitant with matrix metalloproteinase (MMP)-2 expressions
in a UC-MSCs-derived TGF-b fashion (Liu et al., 2016). Although
TGF-b has been recognized as a master factor for the EMT induc-
tion (Xu et al., 2009), other cytokines also contribute to MSCs
capacities to induce EMT in cancer cells; it has been recently
described that the interaction between MSCs and gynecologic
cancer cells (GCC) provokes increased levels of interleukin-6 (IL-
6).
In turn, IL-6 was sufficient to induce EMT program in GCC
concomitantly with elevated levels of MMP2 and MMP9, and
increased cell migration and invasion comparably to TGF-b
treatments (So et al., 2015). Similarly, it has been reported that
BM-MSCs and cells from mesenchymal tumor, osteosarcoma,
communicate by means of TGF-b and IL-6. These interactions
enhance migration and stem cell-like features of HOS and MG63
osteosarcoma cell lines in vitro (Cortini et al., 2016). These results
may suggest that tumor cells provoke an inflammatory response
of MSCs, which in turn expressed elevated levels of IL-6 acting as
a paracrine EMT factor on cancer cells.
Interestingly, HGF/c-Met signaling is recognized to be
involved in regulation of breast cancer progression. Stromal cell
derived HGF promotes stem cell properties of breast epithelial
cells, which is associated with induction of SNAI1 and SNAI2,
the repression of the luminal-regulatory genes Elf5 and Hey1,
and claudin down-regulation (Di-Cico et al., 2015). Also, MSCs
isolated from pancreatic tumor tissue possess characteristics of
myofibroblast, which contribute to the induction of EMT of
PANC-1 and MIAPaCa2 pancreatic cancer cells. MSCs-derived
myofibroblasts stimulate stemness, sphere-forming capacity, in
vivo tumor formation and chemoresistance of tumor cells. Fur-
thermore, the suppression of E-cadherin expression in these pan-
creatic cancer cells was achieved by Notch signaling stimulated
by MSCs (Kabashima-Niibe et al., 2013).
Malignant melanoma (MM) accounts for a high proportion of
deaths from all skin cancers, and EMT has also been suggested to
play an important role in conferring metastatic properties in MM
(Li et al., 2015c). The specific role of MSCs in EMT-like process in
melanoma cells has not widely investigated. Some information
came from Lv et al. (2017) study, where it is shown that in B16
melanoma cells MSCs-derived conditioned medium increase
invasiveness concomitantly with the induction of EMT program,
which involved TGF-b-Snail axis signaling pathway. Further-
more, it has been observed that low extracellular pH (LpH) in
melanoma microenvironment changes metabolic and paracrine
profile of MSCs, stimulating their production of TGF-b and oxi-
dative metabolism. LpH-treated human MSCs produce higher lev-
els of TGF-b, which in turn mediates MSCs-derived conditioned
medium to induce an EMT-like phenotype in A375M6 melanoma
cells.
Moreover, the esomeprazole inhibition of LpH-induced TGF-b
secretion in MSCs, a proton pump inhibitor activated by acidic
medium, seems to develop a MET program as is evidenced by ele-
vation of E-cadherin, reduction of N-cadherin and cell motility
and invasiveness (Peppicelli et al., 2015). Another study also
reported implication of MSCs-derived TGF-b in induction of
EMT-like profile in A375, M21, M14, Hs294T, and in Mewo mela-
noma cells. Intriguingly, the urokinase type plasminogen activa-
tor receptor mediates the capacity of BM-MSC-medium derived
TGF-b to induce EMT and increase malignancy in melanoma
cells (Laurenzana et al., 2015).
As aforementioned, the exosome secretome contributes to EMT
induction by MSCs. Exosomes have been described as novel
mediators of cell-to-cell communication and may acts as a cargo
for several biomolecules such cytokines and microRNAs, among
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et al. (2016) demonstrated that BM-MSC-derived exosomes con-
tain fibroblast growth factor 19, which mediates the induction of
EMT in cancer cells. More recently, MSC-derived exosomes pro-
motes lung cancer EMT by carrying PDGF-D, a newly identified
isoform of PDGFs, concomitantly with increased both in vivo and
in vitro cancer cell migration and proliferation (Huang et al.,
2017). These data exemplify the role of MSC-derived exosomes as
paracrine factors that increase MSCs and cancer cell interactions
to the enhancement of tumor progression by means of EMT-
program expression.
Emerging evidences indicate that cell–cell fusion between
MSCs and tumor cells might contribute to cancer progression
(Noubissi and Ogle, 2016). Xu et al. (2014) describe that cell
fusion is detected both in vivo and in vitro between human BM-
derived MSCs and lung cancer cells. These hybrids display the
EMT features and increase cell motility and tumorigenic poten-
tial. Moreover they express stem cell markers, such as OCT4,
Nanog, and Sox2. Thus, this study proposed that these hybrids
represent novel nonmutational mechanism, which can contribute
to altered gene expression producing high malignant cancer cell
subpopulation with stem cell-like characteristic with enhanced
tumorigenicity and metastatic potential. Another study using a
model of cell fusion, between human UCMSCs and gastric cancer
cells, demonstrated also the formed hybrids exhibit EMT process.
Furthermore, fused cells display both in vivo and in vitro
enhanced growth properties accompanied with increased gastric
cancer cell stemness (Xue et al., 2015).
MSCs repress cancer cell EMT program: MSCs have been dem-
onstrated to possess anti-EMT effects in development of normal
tissues. For instance, prevention of EMT has been observed in
model of lung injury, where it has been observed that MSCs
reduced EMT program initiated by hypoxia in rat alveolar epithe-
lial cell, anti-EMT activity of MSCs has been observed in case of
renal tubular cells, while MSCs derived conditioned media atten-
uated albumin-induced EMT in renal epithelial cells (Uzunhan
et al., 2016; Hu et al., 2015). Although there are no many eviden-
ces concerning anti-EMT effects of MSCs in cancer, there are
some studies which showed such MSC activities. As endometrial
mesenchymal/stromal cells regulate growth and functions of epi-
thelial cells in endometriotic lesions, it has been suggested that
stromal cells participate in pathogenesis of endometrial carcino-
mas. Namely, normal endometrial stromal cells were shown to
inhibit the migration and invasion in endometrial adenocarci-
noma cells (Ishikawa cells). This anti-EMT activity of stromal
cells were followed with decreased Slug expression, increased E-
cadherin expression in Ishikawa cells (Zhang et al., 2016).
Additionally, it has been shown that BM-MSCs can promote
MET program in lung adenocarcinoma cells. Wang et al. (2012)
demonstrated that MSC-derived Oncostatin M, which act as
differentiation-promoting factor, induced MET in cancer cells
mediated by STAT1 signaling pathway, paralleled to the inhibi-
tion of proliferation, cell migration, and invasion of lung adeno-
carcinoma cells. Furthermore, cell–cell interaction also
contributes to the capacity of MSCs to reduce the EMT in head
and neck squamous cell carcinoma PCI-13 cell line by inhibition
of MMP14 expression and Wnt/beta-catenin signal pathway
activity (B€ohrnsen et al., 2015). Recently, it has been observed
that BM-MSCs, although not directly associated with EMT,
decreased breast cancer cell migration and invasion capacity.
This study suggested that the both inhibitors of MMPs TIMP-1
and TIMP-2 mediate these MSCs effects (Clarke et al., 2015) (Fig.
2). However, this study nicely indicated that final outcome of
tumor development is dependent on the balance of all anti- and
pro-tumorigenic activities of MSCs.
Taken together, bidirectional interplay of MSCs and tumor cells
is very complex and underlying mechanisms and the consequences
of this interaction on the cancer-EMT program is not completely
understood. Furthermore, it has been postulated that MSCs favor
MET as reverse process of EMT in tumor cells at distant metastatic
niche, thus promoting tumor cell colonization and progression that
finally consolidates metastasis (del Pozo Martin et al., 2015).
Concluding Remarks and Perspectives
The notion that MSCs play important role in tumor progression,
metastasis, and chemoresistance has been gaining interest in clinic
settings using cell therapies. Although MSCs are well known to
contribute to the healing of damaged tissues, they can be recruited
to the tumor stroma and support tumor growth and progression.
Several properties of MSCs are involved in the cancer cell capacity
to evade immune surveillance, in promotion of angiogenesis and,
what is the main purpose of this review, the induction of EMT in
cancer cell. Emerging clinical and experimental data indicate that
the induction of EMT by MSCs may be related to the poor progno-
sis and cancer recurrence, thus making MSCs as new targets for
the control of tumor progression and holding promise to the
develop of novel anti-tumor therapies (Ridge et al., 2017).
MSCs can use several mechanisms to promote cancer cell EMT.
For instance, the inflammatory tumor niche can reprogram MSCs
to secreted cytokines that directly induce EMT in cancer cells
(e.g., TGF-b). Also, MSCs can augment the stromal levels of ECM
degrading proteins, which contributes to cancer cell invasion,
tumor microenvironment reorganization, and increases the bio-
availability of growth factor inductors of EMT. It is believed that
the intervention against the cancer EMT may provide opportuni-
ties to improve the efficacy of the current chemotherapies and
prevent the development of resistance by cancer cells.
However, some issues should be considered before targeting
MSCs in the tumor microenvironment to effectively control can-
cer EMT to impact tumor progression. MSCs are present in both
stroma of primary tumor and secondary tumors. Thus, it will be
of the great importance to modify the anti-inflammatory proper-
ties of tumor milieu toward an “inflammatory stage” that can
improve immune response and affect the capacity of MSCs, in
situ reprogrammed by cancer cells, which can impact the devel-
opment of cancer EMT.
Moreover, interventions to inhibit either the formation or
release of MSCs-derived factors or exosomes can also improve
the efficacy of onco-therapies that aim to target EMT. Finally,
contribution of MSCs to tumor progression is one of the many
actors in cancer scenario, and it is necessary to develop combined
therapies considering all cellular compartments that can contrib-
ute to the permissive TME in combination with traditional che-
motherapies to prevent or control migration, proliferation and
metastatic outgrowth.
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